Helena Chang

Helena Chang, MD

Professor, Department of Surgery
Director, Revlon/UCLA Breast Center


Chinese, English


Cancer/Surgical Oncology, Surgery General

Institutional Affiliation

Ronald Reagan UCLA Medical Center



Surgery/Oncology, Memorial Sloan-Kettering Cancer Center, 1986 - 1988


MD, Temple University School of Medicine, 1981


Surgery, Episcopal Hospital, 1981 - 1986

Contact Information


(310) 794-7788 - Surgery patient appointments
(310) 206-6909 - Surgical Oncology information and referral
(310) 206-6931 - Surgical Oncology follow-up appointments
(310) 825-2644 - Surgical Oncology referring physician
(310) 825-2144 - Revlon/UCLA Breast Center patient referral coordinator

Clinical Interests


Scientific Interests

Dr. Helena Chang's long-term research interest is in the development of immunotherapy in treating adult ductal epithelial cancer. Chang has developed several recombinant live vaccines that actively secrete a tumor antigen and human cytokines. The role of these vaccines in human cancer treatment and prevention is being investigated. The biological activity of the targeted tumor antigen (MUC-1 peptide) and its involvement in cancer invasion and metastases is being characterized by her research team. She is also working closely with clinician-scientists and basic researchers in studies that characterize breast cancer behavior and develop molecular classifications for locally advanced breast cancer.

Highlighted Publications

He J, Whelan SA, Lu M, Shen D, Chung DU, Saxton RE, Faull KF, Whitelegge JP, Chang HR. Proteomic-based biosignatures in breast cancer classification and prediction of therapeutic response. Int J Proteomics. 2011 Oct 24;2011:896476.

Chang HR, Glaspy J, Allison MA, Kass FC, Elashoff R, Chung DU, Gornbein J. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer. 2010 Sep 15;116(18):4227-37.

Lu M, Whelan SA, He J, Saxton RE, Faull KF, Whitelegge JP, Chang HR. Hydrophobic Proteome Analysis of Triple Negative and Hormone-Receptor-Positive-Her2-Negative Breast Cancer by Mass Spectrometer. Clin Proteomics. 2010 Sep;6(3):93-103.

He J, Shen D, Chung DU, Saxton RE, Whitelegge JP, Faull KF, Chang HR. Tumor proteomic profiling predicts the susceptibility of breast cancer to chemotherapy. Int J Oncol. 2009 Oct;35(4):683-92.

Whelan SA, Lu M, He J, Yan W, Saxton RE, Faull KF, Whitelegge JP, Chang HR. Mass spectrometry (LC-MS/MS) site-mapping of N-glycosylated membrane proteins for breast cancer biomarkers. J Proteome Res. 2009 Aug;8(8):4151-60.